Company News
Granules Files Paragraph IV ANDA for Ruxolitinib ER
Granules India submitted a Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets to the US FDA.
The company believes it is eligible for first-to-file status, potentially granting 180 days of excl
